Neurology
The CGTLive™ Neurology specialty topic page houses video interviews with key opinion leaders in the field of neurology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to cell therapies, gene therapies, and engineered and regenerative medicines developed for neurologic disorders and diseases. It also contains up-to-date clinical news coverage in the field of gene and cell therapy for central nervous system disorders.
Latest News
April 21st 2024
At the 90 day timepoint, the patient showed improvements in swallowing compared to their own natural history data, as measured by videofluoroscopic swallowing studies.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
More News
Long-Term Case Series Supports CAR-T Therapy in Autoimmune Disease
March 28th 2024A 2-year evaluation of a small cohort of patients with systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis showed safety and efficacy which were supportive of additional clinical trials.
Understanding Disease Pathobiology Will be Key to Developing Cell Therapies for Autoimmune Disease
March 26th 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed the importance of further research into the root cause of MS and other autoimmune diseases.
Choosing the Right Patient Populations for CAR-T Clinical Trials in Neurologic Autoimmune Disease
March 21st 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed considerations for evaluating CAR-T in patients most likely to obtain meaningful benefit.
Evaluating Spinal Muscular Atrophy Gene Therapy Zolgensma in Heavier and Older Patients
March 16th 2024Sandra P. Reyna, MD, the chief scientific advisor and head of global medical engagement for SMA at Novartis, discussed data from the phase 3b SMART clinical trial (NCT04851873) that were presented at MDA's 2024 conference.
Open-Label Studies Are Insufficient to Establish the Potential of CAR-T in Autoimmune Disease
March 13th 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed the need for randomized-control trials for CAR-T in lupus and other autoimmune diseases.
